01 October 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company’s Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were duly passed.
06 August 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Catherine Isted, ACMA, who will be joining the Board as Chief Financial Officer effective 11 October 2021.
14 July 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Barbara Staehelin has joined the Board as senior independent Non-Executive Director with immediate effect.
08 July 2021: ReNeuron Group plc (AIM: RENE.L), a UK-based global leader in the development of cell-based therapeutics, announces its preliminary results for the year ended 31 March 2021.
02 July 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2021 on Thursday 8 July 2021.
01 July 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces today that Iain Ross has joined as a Non-Executive Director and Chairman of the Board of Directors with immediate effect. Dr. Tim Corn is stepping down as Chairman of the Board of Directors, but will remain as a Non-Executive Director.
09 June 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides an update on the Company’s Phase 2a clinical evaluations for the treatment of retinitis pigmentosa (‘RP’), an inherited, degenerative eye disease.
20 May 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Dr Stefano Pluchino as Chief Scientific Officer with immediate effect. Dr Pluchino will join the Company on a part-time basis and brings with him a wealth of knowledge of cell and gene therapy.
CEO and CMO to present at Cell & Gene Meeting on the Mediterranean
CEO to present at the Investing in Cures Summit
06 April 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces it will be presenting at two virtual conferences, the virtual Cell & Gene Meeting on the Mediterranean (‘Meeting on the Med’) conference, which takes place on 6-9 April 2021 and the Investing in Cures Summit, “Latest Advances from Clinical Trials and Industry Partnership”, on 12-17 April 2021.
